LFCR: Lifecore Biomedical Inc. EV/EBITDA Multiple

Symbol and logo of brand Lifecore Biomedical Inc. (LFCR)

The current price chart for Lifecore Biomedical (LFCR) demonstrates an EV/EBITDA ratio of 0.00. Stability in these figures is supported by the loyalty of its staff of chemists and specialized engineers, who ensure strict quality control. Lifecore Biomedical creates a unique environment for the development of complex injections, becoming an indispensable link in the supply chains of global tech giants. Earnings are based on the production of sterile preparations and hyaluronic acid for external partners.

LFCR Lifecore: Total Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/10/2026

Analytical breakdowns for Lifecore Biomedical

- stock price and consensus target price:
Stock Quotes Lifecore Biomedical, Inc.|LFCR - Analyst Forecast Prices
- market capitalization information:
Market Capitalization Lifecore Biomedical, Inc.|LFCR - Total Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Lifecore Biomedical|LFCR - Book Valuation of Business|Market Cap to Net Assets Ratio lifecore.com|LFCR - Aggregate Business Assets
- debt and liquidity data:
Debt to Equity Lifecore Biomedical|LFCR - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Lifecore Biomedical, Inc.|LFCR - Company Debts|Debts to Book Capitalization Lifecore Biomedical, Inc.|LFCR - Long-Term Debt Volume|Company Short-Term Debts Lifecore Biomedical|Quick Ratio lifecore.com
- business earnings and investment ratios data:
LFCR - Company Net Income|Projected Future Earnings Lifecore Biomedical|LFCR - Price to Earnings Ratio|Future Price to Earnings Lifecore Biomedical, Inc.|LFCR - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lifecore Biomedical, Inc.|LFCR - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Lifecore Biomedical|LFCR - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months lifecore.com|LFCR - Earnings per share increase in current year|Earnings growth forecast for next year Lifecore Biomedical
Summary company analytics:Lifecore LFCR
Original product of Lifecore Biomedical, Inc.

Investors assess the resilience of capital-intensive enterprises through the ratio of business market value to operating profit. This multiple accounts for debt load and taxes, determining the real value of assets relative to generated cash flow. For Lifecore Biomedical (LFCR), this is critical, as compliance costs for cGMP and FDA standards require massive capital expenditures. The historical EV/EBITDA multiple of the business allows for the timely detection of a dangerous increase in leverage.

Analysis of competing companies

IQVIA Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio LH (LabCorp)|Medpace Holdings, Inc. - EV/EBITDA Multiple|Company Value to EBITDA ICON Public Limited Company|Charles River (CRL) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|EVO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio FTRE|OABI (OmniAb Inc) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inotiv, Inc. (NOTV)|Total Company Value to Operating Income Before Depreciation Ratio avidbio.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalent CTLT|Scorpius Holdings Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization